ReviewPharmaceuticals (Basel, Switzerland)2015
Seatbelts in CAR therapy: How Safe Are CARS?
Review in Pharmaceuticals (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Immunotherapy and radiation for high-grade glioma: a narrative review.Translational cancer research · 2021Review
- Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL PatientsTurkish journal of haematology : official journal of Turkish Society of Haematology · 2020Article
- Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.International journal of molecular sciences · 2020Review
- Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer.Journal of clinical medicine · 2020Review
- A brief review concerning Chimeric Antigen Receptors T cell therapy.Journal of Cancer · 2020Review
- Inverse pharmacology: Approaches and tools for introducing druggability into engineered proteins.Biotechnology advances · 2019Review
- Current Progress in CAR-T Cell Therapy for Solid Tumors.International journal of biological sciences · 2019Review
- A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies.Scientific reports · 2018Article
- Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.Canadian journal of gastroenterology & hepatology · 2018Review
- Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models.American journal of cancer research · 2018Article
- Article
- Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.Oncotarget · 2017Review
- Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.Journal of hematology & oncology · 2017Review
- CAR T-cell therapy for pancreatic cancer.Journal of surgical oncology · 2017Review
- Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease.Biomedicines · 2017Review
- CAR T-cell therapy of solid tumors.Immunology and cell biology · 2017Review
- Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- TriKEs and BiKEs join CARs on the cancer immunotherapy highway.Human vaccines & immunotherapeutics · 2016Article
- Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.Cytotherapy · 2016Review
- Cellular immunotherapy for malignant gliomas.Expert opinion on biological therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cells genetically redirected with a chimeric antigen receptor (CAR) to recognize tumor antigens and kill tumor cells have been infused in several phase 1 clinical trials with success. Due to safety concerns related to on-target/off-tumor effects or cytokine release syndrome, however, strategies to prevent or abate serious adverse events are required. Pharmacologic therapies; suicide genes; or novel strategies to limit the cytotoxic effect only to malignant cells are under active investigations. In this review, we summarize results and toxicities of investigations employing CAR redirected T-cells, with a focus on published strategies to grant safety of this promising cellular application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.